Alpha Teknova, Inc.
Alpha Teknova makes custom and catalog reagents used to discover, develop, and commercialize therapies, vaccines, and molecular diagnostics. Its products are designed for life sciences customers that need high-quality, made-to-order formulations with short turnaround times and consistent manufacturing at scale. The company serves more than 3,000 customers across pharmaceutical and biotechnology companies, CDMOs, diagnostics franchises, and academic and government labs. Teknova’s business is built around configurable manufacturing processes and quality systems that support customers from early research through GMP and commercialization.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueCustomer-specified reagent formulations made to order for research, development, and commercialization workflows.
Standard research-use-only reagents sold from the company’s catalog for routine life sciences applications.
Manufactured reagents used in regulated development and production environments for therapeutic programs.
Reagents and formulations used by diagnostics customers in assay development and commercialization.
Adjacencies such as specialized formulations, support services, and smaller product lines.
Products
Reported · share of revenue- Lab Essentials76.6 %
- Clinical Solutions18.9 %
- Other Product4.5 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Teknova sells into the full life sciences development chain, so its customers include early-stage research labs as well as commercial manufacturers. The largest buyers are pharmaceutical and biotechnology companies that use its reagents in discovery, process development, and production of novel therapies and vaccines. It also serves CDMOs, in vitro diagnostics franchises, and academic and government research institutions that need reliable, fast-turn custom formulations. Customer demand is tied to the success of their own programs, regulatory progress, and end-market adoption, which makes Teknova’s revenue dependent on the health of the broader biotech funding and development cycle.
Buy custom and GMP-grade reagents for discovery, development, and commercialization of therapeutic programs.
Purchase reliable reagent inputs for client projects where consistency, scale, and turnaround time matter.
Use Teknova formulations in assay development and commercialization for molecular diagnostics.
Buy catalog RUO products and custom reagents for research workflows and grant-funded projects.
Need specialized reagents for high-growth therapeutic development and manufacturing workflows.
Strategy
Teknova’s strategy centers on operational excellence: investing in automation, facilities, and manufacturing infrastructure to improve capacity, reduce turnaround time, and support custom production at scale. Management is also trying to deepen customer loyalty by maintaining quality, service, and reliability, which is important because many products become embedded in customers’ workflows and are hard to replace. A second priority is selective geographic expansion, especially into Europe, where the company believes local supply is insufficient for customer-specified formulations with short lead times. The company is also open to partnerships, distribution relationships, and acquisitions that could add capabilities and broaden its addressable market.
Fast, reliable custom manufacturing is the core competitive advantage and supports repeat business.
Products that become embedded in customer processes create recurring demand and switching costs.
The company is highly U.S.-concentrated and sees overseas markets as a long-term growth lever.
Geography
Q1/2026Teknova is heavily concentrated in the United States, where 94.4% of 2025 revenue came from U.S. customers. International sales remain small but are growing faster than domestic sales, and management specifically highlights Europe as a medium- to long-term expansion opportunity. Reported international revenue is currently driven mainly by the United Kingdom, Canada, and Singapore, which indicates a limited but diversified early overseas footprint. The company’s manufacturing and operating base is in Hollister, California, so geography matters both for customer access and for the logistics of short-turn custom fulfillment.
Share of the revenue the company reports by geography.
Risks
Teknova remains exposed to operating losses, competitive pressure, and the cyclicality of biotech and diagnostics demand. Because customers depend on their own regulatory approvals, funding, and market adoption, Teknova can see demand weaken when end markets slow or when customers delay programs. The company also faces execution risk in scaling manufacturing, maintaining quality, and delivering short turnaround times, since those factors are central to its value proposition. International expansion, acquisitions, and cybersecurity are additional risks because they can introduce integration complexity, unfamiliar operating environments, and operational disruption.
- Dependence on customer program successImpact: HighLikelihood: High
Teknova sells inputs to customers whose own products must win regulatory approval and market acceptance.
Exposure - Operating losses and financing needsImpact: HighLikelihood: High
The company has incurred losses and may need continued capital to fund operations and expansion.
Exposure: Liquidity and growth investment
- Manufacturing and supply chain disruptionImpact: HighLikelihood: Medium
Short turnaround times and quality consistency are core to the business, so any disruption can affect delivery and retention.
Exposure - Competitive pressure and in-house substitutionImpact: MediumLikelihood: Medium
Customers may choose larger competitors or produce similar reagents internally if it is cheaper or more convenient.
Exposure: Custom reagents and RUO products
- Cybersecurity incidentImpact: MediumLikelihood: Medium
A breach could interrupt operations, impair systems, or damage reputation and customer trust.
Exposure: Internal systems and third-party data environments
- International expansion and acquisition executionImpact: MediumLikelihood: Low
Entering new markets or integrating acquisitions can create operational and financial complexity without guaranteed payoff.
Exposure: Europe and adjacent markets
Accounting
Judgemental itemsCustom formulations require judgment on contract terms and when control transfers to the customer.
Impact: Can shift revenue timing between periods
Specialized reagents may expire or become unsaleable, requiring write-downs or disposal charges.
Impact: Affects cost of sales and gross margin
Manufacturing, warehouse, and office leases create right-of-use assets and lease liabilities.
Impact: Affects balance sheet leverage and fixed-cost visibility
Non-cash equity awards are part of operating expenses and can materially affect reported losses.
Impact: Affects operating income and earnings comparability
Similar listed companies
Publicly listed companies with a comparable business focus.
AstroNova, Inc.
ALOT · Computer Peripheral Equipment, NEC
Innoviva, Inc.
INVA · Pharmaceutical Preparations
IQVIA Holdings, Inc
IQV · Services-Commercial Physical & Biological Research
RenovoRx, Inc.
RNXT · Surgical & Medical Instruments & Apparatus
HOOKIPA Pharma Inc.
HOOK · Pharmaceutical Preparations
Fortrea Holdings Inc.
FTRE · Services-Medical Laboratories
Last updated: 24/09/2026